Products
HemaFus BCR-ABL1(P210, P190, and P230) Qualitative Detection Kit (PCR-Fluorescent Probing)
Cat. No.:
J0334
Spec:
24 Tests/Kit
Product description
Parameters
Background
Philadelphia chromosome (Ph), characterized by the translocation t(9;22) (q34;q11) and BCR/ABL1 fusion gene, is noted in over 95% of chronic myelocytic leukemia (CML) patients (Figure 1). The BCR-ABL1 fusion gene is present in 25%–30% of adult ALL, 2%–10% of childhood ALL, and less than 2% of AML (lymphoma and myeloma). Meanwhile, a few patients have a simple variant, complex or masked Ph translocation. Three breakpoint cluster regions -- major (M-bcr), minor (m-bcr), and μ (μ-bcr) -- have been characterized to date. The ABL1 gene has a break in intron 1 or 2 (Figure 2).
Ph chromosome or BCR-ABL1 (b2a2 and b3a2) have emerged as the main diagnostic criteria for CML, while ela2 mainly appears in ALL. In CML patients, the typical BCR-ABL1 transcript subtypes are b3a2 (55%) and b2a2 (40%); simultaneous expression of both b3a2 and b2a2 occurs in 5% of CML patients. In addition, BCR/ABL1 e19a2 fusion gene is present in very few Ph+ CML patients. Subtype P210 can be found in 30%–50% of adult Ph+ ALL patients and 20%–30% of childhood Ph+ ALL patients; BCR/ABL1 fusion gene subtype is P190 in 60% of Ph+ ALL patients.
Tyrosine kinase inhibitors (TKIs), such as imatinib, have been used as first-line drugs to achieve a 10-year survival rate of 85%-90% in CML patients who test positive for BCR-ABL1. Second-generation TKIs, such as nilotinib and dasatinib, have also become the first-line treatment option for CML patients as they can achieve faster and deeper molecular responses in the first-line treatment of CML. ALL patients with positive BCR-ABL1 have a poor prognosis with a 5-year survival rate of < 20%. Therefore, these patients require bone marrow transplantation after remission.
Features
Simple operation and less time consumption; reliable results and intuitive interpretation; high sensitivity and sample saving.
Detection Process
Qualitative detection of three types of BCR-ABL1 fusion gene, i.e., P210 (e13a2 and e14a2), P190 (e1a2) and P230 (e19a2), in peripheral blood or bone marrow samples by real-time PCR allows typing detection of P210, P190, and P230, but cannot distinguish between e13a2 and e14a2, in P210.
订购信息
|
货号 |
产品名称 |
规格 |
|
J0334 |
HemaFus BCR-ABL1(P210, P190, and P230) Qualitative Detection Kit
|
24 Tests/Kit |
|
J0388 |
HemaFus BCR-ABL1 Fusion Gene Screening Kit
|
24 Tests/Kit |
|
T0296 |
HemaFus BCR-ABL1(P210) Fusion Gene Quantitative Detection Kit
|
24 Tests/Kit |
|
T0295 |
HemaFus BCR-ABL1(P190) Fusion Gene Quantitative Detection Kit
|
24 Tests/Kit |
|
T0725 |
HemaFus BCR-ABL1(P210) Fusion Gene High Sensitivity Detection Kit |
48 Tests/Kit |
Scan the QR code to read on your phone
